Spots Global Cancer Trial Database for Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Official Title: Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Study ID: NCT04215978
Study Description
Brief Summary: The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanced solid tumors; and to determine the maximum tolerated dose(s) (MTD) or maximum administered dose(s) (MAD) and recommended Phase 2 doses (RP2D) of BGB-A445 alone and in combination with tislelizumab.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
California Cancer Associates For Research and Excellence, Ccare Encinitas, Encinitas, California, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
California Cancer Associates For Research and Excellence, Inc, San Marcos, California, United States
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh, Pennsylvania, United States
Summit Cancer Centers, Spokane Valley, Washington, United States
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales, Australia
Pindara Private Hospital, Benowa, Queensland, Australia
Princess Alexandra Hospital, Brisbane, Queensland, Australia
Monash Health, Clayton, Victoria, Australia
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Juravinski Cancer Centre, Hamilton, Ontario, Canada
National Cancer Center, Goyangsi, Gyeonggido, Korea, Republic of
Seoul National University Bundang Hospital, Seongnamsi, Gyeonggido, Korea, Republic of
The Catholic University of Korea, St Vincents Hospital, Suwonsi, Gyeonggido, Korea, Republic of
Ajou University Hospital, Suwonsi, Gyeonggido, Korea, Republic of
Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Cha Bundang Medical Center, Cha University, Gyeonggido, , Korea, Republic of
Universiti Kebangsaan Malaysia Medical Centre (Ukmmc), Kuala Lumpur, , Malaysia
Auckland City Hospital, Auckland, , New Zealand
Maharaj Nakorn Chiang Mai Hospital (Chiang Mai University), Muang, , Thailand
Sunpasitthiprasong Hospital, Mueang, , Thailand
Contact Details
Name: Study Director
Affiliation: BeiGene
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
